The role of auto-SCT in the treatment of multiple myeloma (MM) in the era of novel agents continues to evolve. It is now clear that the depth of response and clinical outcomes have significantly improved as a result of the combination of these strategies. However, not all patients with MM who undergo auto-SCT are able to sustain a meaningful response and 20% of patients relapse shortly after auto-SCT. In this study, we aimed to assess the impact of early relapse (ER) after auto-SCT on OS for MM patients undergoing single auto-SCT who had received novel agent-based induction regimens. All consecutive patients with MM undergoing single auto-SCT from January 2002 to September 2012 who had novel induction therapy were evaluated. A total of 184 patients were identified. The median OS and PFS for the group of transplanted patients were 93 and 25.4 months, respectively. Median time to relapse was 17.2 months with 40% having relapsed at the time of analysis. ER (o 12 months post auto-SCT) was seen in 27 (36%) out of 75 patients who had relapsed, and median OS was significantly shorter than in those with non-ER. Multivariate analysis showed ER as the major independent prognostic factor for OS. On the basis of these findings, we conclude that not only attainment of a good response, but sustainability of it, appears to be a major prognostic variable in MM in the era of novel therapy. Patients with ER post auto-SCT should biologically be characterized in prospective studies to better understand the mechanisms of resistance associated with this particular entity.
INTRODUCTION
The role of high-dose therapy followed by auto-SCT in the treatment of multiple myeloma (MM) continues to evolve in the novel agent (NA) era. 3 Although auto-SCT can result in sustained responses in a large group of patients,~20% of the patients relapse within a year from auto-SCT. 4 Kumar et al., 5 reported a multivariate analysis in a group of 494 patients treated mostly with conventional chemotherapy induction followed by auto-SCT showing that only an elevated plasma cell labeling index (41%) at transplant, more than one treatment regimen prior to auto-SCT, and failure to achieve a CR were predictive of relapse within 12 months of auto-SCT. 5 No association with abnormal cytogenetics was found in the multivariate analysis even in the small group of patients assessed by FISH.
It has also been demonstrated that exposure to NAs can improve post-relapse survival. 6 Recently, Hoering et al., 7 reported in a large group of 41000 patients (TT1, TT2 and TT3) that both failure to achieve CR and, especially, loss of CR were independently associated with inferior survival. 7 Furthermore, Paiva et al., 8 demonstrated that patients who lose their CR status within 1 year post auto-SCT have poor prognosis, suggesting the importance of identifying such cases. 8 In the multivariate analysis, the presence of high-risk cytogenetics detected by FISH and persistent minimal residual disease detected by multiparameter flow cytometry at day 100 post auto-SCT were the only independent factors to predict unsustained CR. Hence, in the present study, we aimed to assess the impact of early relapse (ER) after auto-SCT on OS for MM patients undergoing single auto-SCT who had received NA induction regimens, and to analyze whether any predictors of ER could be identified.
MATERIALS AND METHODS

Patient population
All consecutive patients who underwent single auto-SCT at Princess Margaret Cancer Center (PM) from January 2002 to September 2012 that received NAs induction chemotherapy as first-line therapy were evaluated. To be included in the study, patients were required to be transplanted, followed and treated at the PM. Patients were also excluded if they had a concurrent malignant diagnosis, any other plasma cell disorder or if a tandem transplant approach was performed. Approval for the review of these records was obtained from the PM Institutional Review Board and was in accordance with the Declaration of Helsinki. Our programme requires patients to achieve at least PR or better after induction chemotherapy to be considered for auto-SCT, however, eight cases were transplanted even when only minimal response (MR) (n = 2) and s.d. (n = 6) was achieved after induction chemotherapy.
Induction chemotherapy regimens
One-hundred and nineteen patients (64.7%) were treated with proteasome inhibitor (PI) combinations, whereas 65 (35.3%) received immunomodulatory drug-based regimens. Induction regimens were given as follows: CY 300 mg/m 2 orally once weekly, dexamethasone 40 mg once weekly and bortezomib 1. Stem cell mobilization and high-dose melphalan All patients received induction chemotherapy with NAs before undergoing auto-SCT and the type of regimen employed was recorded. Standard supportive care with prophylactic antibiotics was provided to all patients. As part of the auto-SCT process, the stem cells were obtained from the peripheral blood with G-CSF (10 μg per kilogram of body weight s.c., once daily) and i.v. CY (2.5 g/m 2 ). Patients received high-dose melphalan at 200 mg/m 2 (or adjusted as per renal function), given i.v. on day − 1, and stem cells were infused on day 0. Pre-transplant assessments were performed according to our center guidelines and data were extracted from the medical charts.
Response assessment
Definitions of response and progression were used according to the European Group for Blood and Marrow Transplant modified criteria and a category of very good PR (VGPR) was added. 9, 10 Responses were categorized as CR if there was disappearance of monoclonal protein in the serum and urine by electrophoresis and immunofixation, disappearance of any soft tissue plasmacytoma and o5% plasma cells in BM, as well as normalization of the free-light-chain ratio. VGPR was defined as serum and urine M-component detectable by immunofixation but not by electrophoresis, or ⩾ 90% reduction in the serum M-component plus urine M-component o100 mg per 24 h. PFS was defined as the time from auto-SCT to disease progression or death, whereas OS was defined from the date of auto-SCT to the date of death from any cause. 10 Responses were assessed before auto-SCT and at day 100 post auto-SCT as per our clinical guidelines. Early assessments were rare and performed as per physician discretion.
Definition of ER
ER was defined as relapse or progressive disease as per the standard International Myeloma Working Group criteria that occurred within 12 months from the time of auto-SCT. 5 For patients who undergo SCT, one of the most important factors to determine survival is the duration of remission post auto-SCT and o 12 months was selected, based on previous publications on this issue. 5, 6 End points
The primary end point of the study was to assess the impact of ER on OS; and secondary end points included the assessment of possible predictive markers for ER including cytogenetic and serological markers, as well as PFS rates for patients undergoing single auto-SCT after NAs induction chemotherapy.
Statistical analyses
The role of ER on OS was evaluated and differences in continuous variables between groups were compared using Mann-Whitney or Kruskal-Wallis tests. The Cox proportional hazard model was used to perform univariate and multivariate analyses of possible prognostic variables for OS, after confirming the proportionality of each variable using time-dependent covariates. The variables included in the univariate and multivariate analyses were: age 460 years, beta-2 microglobulin (β2M) 4460 μmol/L, lactate dehydrogenase 4350 IU/L, C-reactive protein 420 mg/L, albumin o35 g/L, creatinine4200 μmol/L, type of induction regimen given, ER category, achievement of ⩾ VGPR at day 100 post auto-SCT and high-risk cytogenetics defined by the presence of either t(4;14), t(14;16) and 17p deletion detected by FISH assessment. Cox analysis was performed using backward stepwise selection methods. Survival curves were constructed according to the Kaplan-Meier method and compared using the log rank test. All analyses were performed using the SPSS 20.0 software (IBM Statistics, San Francisco, CA, USA). All P-values were two sided and statistically significant if o0.05.
RESULTS
Patient characteristics
Between January 2002 and September 2012, 184 patients were identified for the study. Clinical and laboratory characteristicsare listed in Table 1 . The median age for this cohort of patients was 58 years (range 31-72). Clinical characteristics were similar between patients receiving PI-based induction vs immunomodulatory drug. However, some differences between International Staging System (ISS) stages and heavy-chain distribution were noted (Table 1) .
Forty-eight percent of patients received CyBorD, 27.2% thalidomide and dexamethasone, 7.1% doxil, bortezomib and dexamethasone, 8.7% bortezomib and dexamethasone and 8.2% received lenalidomide and dexamethasone as induction chemotherapy (Table 2 ). Median time from myeloma diagnosis to auto-SCT was 5 months.
Hematological response and survival After induction chemotherapy, CR was seen in 13.1% and VGPR in 51.4% ( ⩾ VGPR of 64.5%) of cases. After a median of 4 cycles of induction chemotherapy, best response to induction regimens showed a ⩾ VGPR in 62% of patients treated with CyBORD, 66% of those receiving lenalidomide and dexamthasone, 24% of patients treated with thalidomide and dexamethasone, 38% of patients treated with doxil, bortezomib and dexamethasone and 62% of the cases receiving bortezomib and dexamethasone (P = 0.015 for thalidomide plus dexamethasone and doxil, bortezomib and dexamethasone compared with the others).
At day 100 post auto-SCT, CR was achieved in 15.3% and VGPR in 57.1% (72.4%). VGPR or higher at day 100 post auto-SCT was seen in 72% of patients treated with CyBorD, 100% of those receiving lenalidomide and dexamethasone, 58% of patients treated with doxil, bortezomib and dexamethasone, 68% of the cases receiving bortezomib and dexamethasone and 70% of (Figure 1a ). In addition, median PFS was 25.4 months for the whole group of MM patients undergoing single auto-SCT. Median time to relapse was 17.2 months (95% CI: 12-22). ER was seen in 27 of 75 relapsed patients (36%). ER was most commonly seen in patients receiving thalidomide induction regimens (12/27, 44%) compared with the other induction combinations (P = 0.04).
Median OS was significantly shorter for the group of patients with ER (20 months, 95% CI: 15.56-24.51 vs 93 months, 95% CI: 75-111) (P = 0.001) (Figure 1b) . Patients with ER showed a lower ⩾ VGPR rate that those with non-ER and median OS was shorter in the group of patients who achieved ⩾ VGPR with ER compared with those who achieved ⩾ VGPR but who did not exhibit ER (median OS of 79.3 months, 95% CI: 64.63-94.1 vs 38.53 months, 95% CI: 18.58-58.38, P = 0.013) (Figure 2 ). Overall, there was a trend to better OS for patients achieving ⩾ VGPR in the whole group of patients (not-reached vs 79 months) but was not statistically significant (P = 0.059) (Figure 3 ).
Furthermore, median OS has not been reached for the group treated with PI (mean 78.12 months, 95% CI: 67.5-88.6) compared to a median OS of 77 months (95% CI: 59.2-95.2) for the group treated with immunomodulatory drugs induction (P = 0.16).
In addition, median OS was shorter for the group of patients with β2M4 460 μmol/L, 39 months (95% CI: 16.1-62.2) compared with 93.4 months (95% CI: 63.8-122.9) (P = 0.0001) for those patients with a lower value at diagnosis (Figure 4 ).
Multivariate analysis
Prognostic variables were examined for significance in univariate analyses including: age, best response to induction chemotherapy, best response at day 100 post auto-SCT, induction regimen, β2M, Hb, creatinine, albumin, lactate dehydrogenase, C-reactive protein and ER post auto-SCT. β2M at diagnosis was missed in a significant number of patients (n = 42) that were referred to us after initiating treatment and therefore, the value at presentation was recorded in all of them, however, to avoid bias β2M at diagnosis was used for the analysis. Multivariate analysis showed the presence of ER as well as β2M4 460 μmol/L as the unique independent prognostic factors for OS (P = 0.001 and P = 0.003, respectively). Cytogenetic abnormalities detected by FISH were available in 78 out of 184 cases and only 1 patient out of 27 with ER and 0/48 patients with non-ER exhibited high-risk features ((p53 deletion, t(4;14), and t(14;16)) (P = 0.5) ( Table 3) .
DISCUSSION
In the last decade, the introduction of NAs for the treatment of MM, has significantly improved clinical outcomes including response rates and OS. 11, 12 Still, not all patients respond to these new drugs and, furthermore, some patients relapse quickly regardless of the previous response achievement, suggesting that some biological mechanisms of resistance emerge in such aggressive myeloma clones. Furthermore, the existence of a progenitor organization in primary MM that recapitulates maturation stages between B cells and plasma cells and that contributes to clinical resistance in relapsed myeloma patients has also been recognized. 13, 14 Leung-Hagesteijn et al. 13 recently demonstrated that MM cells achieve bortezomib resistance via de-commitment to terminal plasma cell maturation, others have instead found that this resistance could be related to plasmacytic differentiation. 15 Nonetheless, the use of NAs during the induction phase followed by auto-SCT has been associated with improvement in the quality of responses, with a higher number of patients achieving VGPR or better, which in turn translates into a major benefit for OS and PFS. 6, 12, 16, 17 Although auto-SCT after NAs induction can result in sustained responses in the majority of cases, still there are some patients relapsing within a year after auto-SCT and this group has poorly been characterized. 5 In this study, we presented our data on ER for patients undergoing single auto-SCT who received NAs induction chemotherapy at our institution in a period of 10 years. The median survival for the whole group was 93 months showing a great benefit associated with the introduction of NAs. With the use of NAs, the rate of VGPR or higher was 64.5% before auto-SCT and 72% at day 100 post auto-SCT. A significant number of patients was treated with CyBORD (48.8%), but also lenalidomide and thalidomide combinations were included. As reported by some other groups not only the quality of response but also its durability is important. 18 Sustainability of CR has been reported as an important factor to consider while trying to improve clinical outcomes, and efforts have been made with regards to identifying predictor markers based on the use of FISH cytogenetics and multiparameter flow cytometry to define a high-risk group for ER and inferior survival (persistent minimal residual disease, p53 del, t(14;16) and t(4;14)). 7, 8 In the current report, ER was identified in 27 patients (14.6%) and median OS was significantly shorter for this group (20 months). Achievement of ⩾ VGPR and non-ER were associated with better OS in the univariate analysis, but multivariate analysis showed the presence of ER and β2M4 460 μmol/L as the most important independent prognostic factors for OS (P = 0.001 and 0.003, respectively). Patients receiving thalidomide-containing induction regimens exhibited a lower rate of VGPR or higher after induction and an increased rate of ER compared with the other induction regimens (P = 0.01 and 0.04, respectively), suggesting that second-generation immunomodulatory drugs and PIs might be better options to prevent ER to occur in the setting of auto-SCT. Nonetheless, OS was similar for those patients treated with PI or immunomodulatory drugs-based induction therapy. There was a trend to better OS for patients achieving ⩾ VGPR in the whole group of patients (not-reached vs 79 months), but was not statistically significant (P = 0.059).
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Given the strong prognostic value of cytogenetic features such as t(4;14), t(14;16) and p53 abnormalities on the outcome after auto-SCT, we examined ER as a prognostic factor in the context of these variables in our data set. Only 1 of the 27 cases with ER and none on the non-ER group exhibited high-risk cytogenetics by FISH analysis. Unfortunately, we lack of results for 1p deletion and 1q amplification that recently have been identified as genetic progression factors. 19 One limitation in this setting from our study is the small number of cases with a full genetic analysis and thus a more comprehensive biological characterization is needed.
In addition, a multivariate analysis was performed and not statistically significant differences were noted for age at diagnosis or transplant, M-protein level, BM plasma cell percentage, lactate dehydrogenase, gender, creatinine, presence of bone lesions, heavy-chain subtype or free-light-chain levels. Other prognostic markers such as plasma cell labeling index and circulating plasma cells at stem cell collection have been reported as predictors of ER by the Mayo Clinic group in the setting of conventional chemotherapy. 5 Unfortunately, the plasma cell labeling index is not widely used due to the technical difficulties that make it less appealing to employ. We did not look for circulating plasma cells at the time of stem cell collection but this is something that should be interrogated in the era of NAs, as patients exposed to these drugs are deemed to have deeper responses than those treated with conventional chemotherapy in the past.
Some other limitations of the current report are the inability to look at the impact of depth of response fully (stringent CR) and minimal residual disease that could be associated to a shorter PFS. Nonetheless, our study provides with new insights with regard to the variability of response among the different induction regimens and the impact of auto-SCT to improve the response at day 100 post auto-SCT.
On the basis of our study findings, we conclude that ER after auto-SCT appears to be a major prognostic variable in MM. Patients with ER post auto-SCT should biologically be characterized in prospective studies to better understand the mechanisms of resistance associated with this particular entity. As patients with ER exhibited a lower rate of VGPR or higher, new-generation drugs (that is, pomalidomide, carfilzomib or monoclonal antibodies) and strategies such as consolidation or maintenance should be considered especially for those patients where there is a high tumor burden. Studies on minimal residual disease and a more broad and deep panel of cytogenetics will help identifying some intrinsic biological factors that could be associated with lack of response sustainability.
